Genuine extension into a new disease
The cHK analysis extends contact-system biomarker work from anaphylaxis and HAE into a broader CSU cohort, including patients without angioedema.
↳ Introduction; Results §3.1, Figure 1A–C; Discussion p. 348
Abstract
BACKGROUND: Chronic spontaneous urticaria (CSU) is characterized by recurrent itchy weals and/or angioedema and is believed to be driven by mast cell activation. It was shown that excessive mast cell activation during anaphylaxis initiates contact activation, resulting in bradykinin release. Evidence for bradykinin release was never demonstrated in CSU. OBJECTIVE: To study biomarkers of bradykinin release in CSU. METHODS: Plasma samples of CSU patients were collected during routine visits at the outpatient clinic. Cleaved high molecular weight kininogen (cHK) was used as a biomarker for bradykinin release. cHK, factor XIIa-C1-inhibitor (FXIIa-C1-INH), kallikrein-C1-INH, plasmin-antiplasmin (PAP) complexes and soluble urokinase-type plasminogen activator receptor (suPAR) levels were determined by ELISA. Clinical data and data on tryptase levels were collected from medical records. cHK levels were compared to previously determined levels in hereditary angioedema (HAE). RESULTS: One hundred seventeen samples from 88 CSU patients and 28 samples from healthy controls were analysed. Median cHK level in CSU was 9.1% (range: 1.4%-21.5%), significantly increased compared to healthy controls (median 6.0% range: 0%-19.9%; P = .0005) and comparable to HAE (n = 46, median 10.3%, range 0%-44.3%, P > .9999). cHK levels normalized in patients during disease remission (median 6.5% range 1.5%-20.8%) but were not dependent on the presence of angioedema, acute angioedema attacks or response to antihistamines. Surprisingly, cHK levels were inversely correlated to serum tryptase (r = -0.65 P = .0137). C1-INH complexes and suPAR levels were not elevated in patients compared to healthy controls. PAP-complex levels in patients were elevated compared to healthy controls but there was no correlation between PAP-complex and cHK levels. CONCLUSIONS: cHK levels are elevated in symptomatic CSU patients compared to healthy controls, indicating increased bradykinin production. Increased cHK levels are not limited to patients with angioedema. CLINICAL RELEVANCE: If elevated bradykinin generation has clinical implications in the pathology of CSU is open to debate.
Key Claims
Primary findingTentative
cHK levels are elevated in symptomatic CSU patients compared to healthy controls, indicating increased bradykinin production.
Fragile — the claim's weakest requirement is that the effect exists at all. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.
indirect biomarker inference from groups with non-equivalent sample handling and a discrepant reported P-value
Abstract, Conclusions; Results §3.1, Figure 1A
SecondaryWell-supported
Increased cHK levels are not limited to patients with angioedema.
phenotype comparisons found no cHK difference across weals and angioedema groups
Abstract, Conclusions; Results §3.1, Figure 1C
SecondarySupported
cHK levels normalized in patients during disease remission.
selected repeated observations support lower remission levels, though one symptomatic pairwise comparison was non-significant
Abstract; Results §3.1, Figure 1B
SecondaryTentative
cHK levels were inversely correlated to serum tryptase (r = -0.65 P = .0137).
the association rests on 14 same-day measurements and varies across alternative tryptase subsets
Abstract; Results §3.1, Figure 1F
Derived from the full evaluation — not a separate score.
Strengths · Limitations
Strengths
Detailed biomarker assay methodology
The paper specifies the ELISA calibration procedures and uses protease-inhibitor collection tubes for CSU samples to reduce post-draw contact activation.
↳ Methods §§2.1–2.2
Clinical implications remain explicitly bounded
The abstract and discussion state that pathological relevance remains uncertain and frame bradykinin as a proposed component of a multifactorial model rather than an established cause.
↳ Abstract, Clinical Relevance; Discussion pp. 349–350
Limitations
Non-equivalent patient-control sample handling
CSU plasma was collected in PPACK-containing SCAT tubes, whereas healthy-control plasma used standard citrate tubes and a different centrifugation protocol. The possible effect on cHK, a pre-analytically sensitive marker, was not assessed.
↳ Methods §2.1
Headline statistics are internally inconsistent
The abstract reports P = .0005 for the principal CSU–control comparison, while Results §3.1 reports P = .0056. Figure 1 also analyses 86 patients without reconciling that denominator with the 88 included patients.
↳ Abstract; Results §3.1; Figure 1A legend
Secondary analyses use limited samples
The inverse cHK–tryptase correlation relies on 14 same-day measurements, and other tryptase subsets give weaker or non-significant results. Repeated severity measurements also arise from selected follow-up visits.
↳ Methods §2.2; Results §3.1, Figure 1F and Supplemental Figures 2 and 4
Nabu Commentary
The contribution score reflects a genuine extension of cHK measurement into CSU, including remission and phenotype comparisons in Results §3.1. Methodological Rigour is lower because Methods §2.1 documents different collection tubes and processing for patients and controls, while selected follow-up visits and unmodelled repeated observations constrain longitudinal interpretation. Reporting and Positioning score higher because the Discussion engages conflicting prior findings and repeatedly limits claims about pathology and clinical relevance. The central result remains preliminary until it is reproduced with standardized pre-analytics and an independently recruited cohort.
Check another paper
Author Note / Field Feedback
Nabu’s assessment, alongside the field’s view.
Are you an author of this paper?
Dimension breakdown
Study Quality
Sound3.3
Confidence highContribution
3.5
The study adds a genuinely new cHK observation in symptomatic CSU and examines its relationship to remission and angioedema phenotype. The advance remains a narrowly scoped, hypothesis-generating biomarker result rather than evidence of a causal or clinically actionable role.
Results §3.1, Figure 1A–C; Discussion, pp. 348–350
“we cautiously introduce the idea of including bradykinin in this multifactorial model”
Methodological Rigour
3.0
The ELISA procedures and calibration are described in detail, but CSU and control samples underwent different collection and processing procedures for a pre-analytically sensitive biomarker. Tertiary referral and selected repeated visits also limit subgroup and longitudinal analyses.
Methods §§2.1–2.3; Results §3.1, Figure 1B; Discussion p. 350
“A referral bias is possible”
Reporting
3.8
The paper presents a traceable progression from contact-system rationale to biomarker results and explicitly separates biochemical evidence from uncertain clinical relevance. The inconsistent headline P-value reduces numerical precision but does not disrupt the argument’s direction.
Abstract; Results §3.1; Discussion pp. 348–350
“If elevated bradykinin generation has clinical implications in the pathology of CSU is open to debate.”
Positioning
3.6
The discussion compares the findings with anaphylaxis, HAE, idiopathic angioedema, and prior Western-blot evidence while explaining several divergent results. It acknowledges referral bias and the small tryptase subset but does not trace the patient-control collection mismatch to the central comparison.
Discussion, pp. 348–350
“To confirm our finding in CSU, replication in a larger cohort is necessary”
Lower confidence on Contribution, Methodological Rigour — domain match limited.
Reliability
Caveats4 of 4 checks
Internal CoherenceNoted
The central cHK comparison is directionally consistent but contains a discrepant P-value across sections, and the analysed cHK denominator is not reconciled with the enrolled cohort.
Research ConductClean
Ethics approval and written consent are declared for both cohorts, conflicts are disclosed, and a data-access statement is provided. No text-visible research-conduct concern was identified.
Flags: 3 declared / 5 total
Reference IntegrityClean
39 of 39 checkable references verified
39 references in manuscript
Post-Publication RecordClean
No retraction notice found in Retraction Watch.
Last checked: 18 Sep 2026
Sources: Retraction Watch ✓
Readiness
Where this paper’s evidence sits on the path from initial observation to real-world use.
Mechanistic
This is an initial observational biomarker study without an intervention, diagnostic validation, treatment recommendation, or demonstrated clinical utility. The authors explicitly leave the clinical significance unresolved.
Abstract, Clinical Relevance; Discussion pp. 349–350
“remains to be answered”
AI-generated, human-governed. Something look off? Contact us to request a review.